Boston Scientific Corporation (BSX) Tuesday said it received Food and Drug Administration's approval for the expanded indication of INGEVITY+ Pacing Leads to include conduction system pacing (CSP) of the left bundle branch area (LBBA).
Pacing of the LBBA is an alternative to traditional right ventricular pacing for the treatment of symptomatic bradycardia, a condition in which the heart beats too slowly.
"We believe the expanded indication for the INGEVITY+ Pacing Lead will enhance the implant experience for physicians and connect this technology to the growing number of patients who can benefit from LBBA pacing," said Scott Olson, senior vice president and president, Cardiac Rhythm Management and Diagnostics, Boston Scientific.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.